Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.38 |
| ▸ | FNTB | P49356 | 5/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988729 | 0.97 | FNTA (0.38) | FNTAFNTBOPRL1OPRM1OPRK1 | |
| SCHEMBL4993053 | 0.93 | FNTA (0.41) | FNTAFNTBOPRL1OPRM1OPRK1 | |
| SCHEMBL4993661 | 0.87 | FNTA (0.38) | FNTAFNTBSMN1; SMN2ACEUBE2N | |
| SCHEMBL4988873 | 0.87 | OPRL1 (0.39) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4990383 | 0.83 | PSEN1 (0.39) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4985924 | 0.82 | SMYD3 (0.39) | FNTAFNTBACEUBE2N | |
| SCHEMBL4995441 | 0.82 | NPC1 (0.42) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4992212 | 0.81 | OPRL1 (0.41) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4993124 | 0.80 | OPRL1 (0.40) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4991390 | 0.79 | IL2RA (0.39) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020052359-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052359-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | FNTA 239/4885FNTB 322/4885OPRL1 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.